Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 4
2006 3
2007 2
2008 7
2009 5
2010 8
2011 7
2012 4
2013 8
2014 6
2015 9
2016 5
2017 2
2019 6
2020 12
2021 7
2022 10
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM, Giordano M, Garrone O, Arpino G, Poggio F, Cinacchi P, Bighin C, Fregatti P, Pronzato P, Blondeaux E, Del Mastro L; GIM study group. Lambertini M, et al. Among authors: pronzato p. J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213. J Natl Cancer Inst. 2022. PMID: 34850043 Free PMC article. Clinical Trial.
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A, Tanda ET, Croce E, Catalano F, Ceppi M, Bruzzone M, Cecchi F, Arecco L, Fraguglia M, Pronzato P, Genova C, Del Mastro L, Lambertini M, Spagnolo F. Boutros A, et al. Among authors: pronzato p. Eur J Cancer. 2023 Jul;188:64-79. doi: 10.1016/j.ejca.2023.04.010. Epub 2023 Apr 24. Eur J Cancer. 2023. PMID: 37196485 Free article. Review.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8. Lancet. 2019. PMID: 30739743 Free PMC article.
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C, Tasso R, Rosa A, Rossi G, Reverberi D, Fontana V, Marconi S, Croce M, Dal Bello MG, Dellepiane C, Tagliamento M, Ciferri MC, Zullo L, Fedeli A, Alama A, Cortese K, Gentili C, Cella E, Anselmi G, Mora M, Barletta G, Rijavec E, Grossi F, Pronzato P, Coco S. Genova C, et al. Among authors: pronzato p. Cells. 2023 Mar 8;12(6):832. doi: 10.3390/cells12060832. Cells. 2023. PMID: 36980174 Free PMC article.
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
Rescigno M, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Rescigno M, et al. Front Immunol. 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124. eCollection 2023. Front Immunol. 2023. PMID: 36776853 Free PMC article.
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R, Queirolo P, Gerard Duhard P, Hu Y, Wang D, de Azevedo SJ, Robert C, Ascierto PA, Chiarion-Sileni V, Pronzato P, Spagnolo F, Mujika Eizmendi K, Liszkay G, de la Cruz Merino L, Tawbi H. Dummer R, et al. Among authors: pronzato p. Lancet Oncol. 2023 Dec;24(12):e461-e471. doi: 10.1016/S1470-2045(23)00334-0. Epub 2023 Jul 14. Lancet Oncol. 2023. PMID: 37459873
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.
Cella E, Zullo L, Marconi S, Rossi G, Coco S, Dellepiane C, Alama A, Rozeboom L, Bennicelli E, Parisi F, Sacco G, Barletta G, Zinoli L, Tagliamento M, Pronzato P, Genova C. Cella E, et al. Among authors: pronzato p. Expert Opin Biol Ther. 2022 Oct;22(10):1259-1273. doi: 10.1080/14712598.2022.2116273. Epub 2022 Aug 28. Expert Opin Biol Ther. 2022. PMID: 35994596 Review.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA. Frassoldati A, et al. Among authors: pronzato p. Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18. Future Oncol. 2020. PMID: 31849236 Review.
97 results